^
Association details:
Biomarker:No biomarker
Cancer:Squamous Cell Carcinoma of Head and Neck
Drug:cisplatin (DNA synthesis inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
Title:

Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Published date:
11/01/2020
Excerpt:
The standard of care for ChT is cisplatin at a dose of 100 mg/m2 given on days 1, 22 and 43 of concomitant RT (70 Gy) [II, A].
DOI:
10.1016/j.annonc.2020.07.011